Pancreatic Cancer Research

ResearcherChiba UniversityActive in the last 2 years

Shingo Kagawa

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5102252074. Sources: OpenAlex.

Their work

Papers
22 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
61
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 2 papers · 2015: 2 papers · 2016: 3 papers · 2017: 4 papers · 2018: 2 papers · 2019: 2 papers · 2020: 2 papers · 2021: 2 papers · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 22

  1. Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geria… Co-author DOI 10.1093/jjco/hyag055↗
  2. [Successful Resection of a Metachronous Liver Metastasis after Pancreatic Ductal Adenocarcinoma Surgery-A Case with Two-Year Recurrence-Free Survival]. First author PMID 41546317↗
  3. Complement factor B regulates cellular senescence and is associated with poor prognosis in pancreatic cancer. Co-author DOI 10.1007/s13402-021-00614-z↗
  4. Simultaneous brain and lung metastases of pancreatic ductal adenocarcinoma after curative pancreatectomy: a case report and literature review. Co-author DOI 10.1186/s12876-020-01587-3↗
  5. Needle tract seeding recurrence of pancreatic cancer in the gastric wall with paragastric lymph node metastasis after endoscopic ultrasound-guided fine needle … Co-author DOI 10.1186/s12876-020-1159-x↗
  6. [Ⅱ.Carbon Ion Radiation Therapy as Perioperative Treatment for Pancreatic Cancer]. Co-author PMID 33130735↗
  7. Is hepatic artery coil embolization useful in distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic cancer? Co-author DOI 10.1186/s12957-019-1667-8↗
  8. Successful treatment of a locally advanced unresectable pancreatic cancer patient with interstitial pneumonitis by conversion surgery following gemcitabine plu… Co-author DOI 10.3892/mco.2019.1807↗
  9. Expression of annexin II and stromal tenascin C promotes epithelial to mesenchymal transition and correlates with distant metastasis in pancreatic cancer. Co-author DOI 10.3892/ijmm.2018.3652↗
  10. Conversion surgery with gemcitabine plus nab-paclitaxel for locally advanced unresectable pancreatic cancer: A case report. Co-author DOI 10.3892/mco.2018.1688↗
  11. Grainyhead-like 2 (GRHL2) regulates epithelial plasticity in pancreatic cancer progression. Co-author DOI 10.1002/cam4.1212↗
  12. Sex Determining Region Y Box 9 Induces Chemoresistance in Pancreatic Cancer Cells by Induction of Putative Cancer Stem Cell Characteristics and Its High Expres… Co-author DOI 10.1097/mpa.0000000000000945↗
  13. Metadherin promotes metastasis by supporting putative cancer stem cell properties and epithelial plasticity in pancreatic cancer. Co-author DOI 10.18632/oncotarget.19802↗
  14. [IV. Distal Pancreatectomy with Celiac Axis Resection(DP-CAR)for Locally Advanced Pancreatic Cancer with Celiac Artery Invasion]. Co-author PMID 29066679↗
  15. Low Stromal Area and High Stromal Microvessel Density Predict Poor Prognosis in Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000499↗
  16. [Two Cases of Remnant Pancreatic Cancer Treated Using Remnant Pancreatectomy Combined with Hepatic Arterial Resection]. Co-author PMID 28133092↗
  17. [A Case of Early-Onset Rapidly Progressive Cerebral Infarction with Trousseau's Syndrome in a Patient with Pancreatic Cancer Undergoing Surgery]. Co-author PMID 28133197↗
  18. [III. Repeat pancreatectomy for recurrent pancreatic cancer]. Co-author PMID 26665417↗
  19. [A Case of R0 Resection of Locally Advanced Pancreatic Cancer Following Chemoradiation Therapy]. Co-author PMID 26805371↗
  20. Tips and tricks of surgical technique for pancreatic cancer: portal vein resection and reconstruction (with videos). Co-author DOI 10.1002/jhbp.128↗
  21. [Liver, pancreas, biliary tract cancer. III. Pancreatectomy with Vascular Resection for Locally Advanced Pancreatic Cancer]. Co-author PMID 25528776↗
  22. Akt/mTOR signaling pathway is crucial for gemcitabine resistance induced by Annexin II in pancreatic cancer cells. Co-author DOI 10.1016/j.jss.2012.05.065↗

Closest collaborators

The 25 strongest of 61 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shigetsugu Takano · 20 shared papers, 2012–2021 · strength 1.35
  2. Katsunori Furukawa · 19 shared papers, 2012–2021 · strength 1.24
  3. Hideyuki Yoshitomi · 19 shared papers, 2012–2021 · strength 1.24
  4. Masayuki Ohtsuka · 18 shared papers, 2012–2021 · strength 1.21
  5. Masaru Miyazaki · 17 shared papers, 2012–2021 · strength 1.06
  6. Norikazu Yogi · 2 shared papers, 2016–2025 · strength 0.32
  7. Yosuke Iwatate · 1 shared paper, 2025 · strength 0.27
  8. Fumitaka Ishige · 1 shared paper, 2025 · strength 0.27
  9. Atsushi Kato · 1 shared paper, 2025 · strength 0.27
  10. Hidehito Arimitsu · 1 shared paper, 2025 · strength 0.27
  11. Reiri Shimazaki · 3 shared papers, 2017–2021 · strength 0.25
  12. Atsuhiko Ueda · 3 shared papers, 2016–2019 · strength 0.20
  13. Amane Takahashi · 1 shared paper, 2026 · strength 0.20
  14. Shiho Arima · 1 shared paper, 2026 · strength 0.20
  15. Masaaki Murakawa · 1 shared paper, 2026 · strength 0.20
  16. Shintaro Yagi · 1 shared paper, 2026 · strength 0.20
  17. Toru Otsuru · 1 shared paper, 2026 · strength 0.20
  18. Yusuke Sano · 1 shared paper, 2026 · strength 0.20
  19. Keiko Kamei · 1 shared paper, 2026 · strength 0.20
  20. Kazuaki Harada · 1 shared paper, 2026 · strength 0.20
  21. Nobumasa Mizuno · 1 shared paper, 2026 · strength 0.20
  22. Hidetoshi Eguchi · 1 shared paper, 2026 · strength 0.20
  23. Hirofumi Akita · 1 shared paper, 2026 · strength 0.20
  24. Naohiro Okano · 1 shared paper, 2026 · strength 0.20
  25. Naoto Gotohda · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.